Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
JW Capital
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
JW Therapeutics’ lead product, relmacabtagene autoleucel (relma-cel), is approved in China for relapsed/refractory large B-cell lymphoma; additional programs are in clinical and preclinical stages for hematologic and solid cancers.
- Therapeutic areas
- OncologyHematologyImmunology
- Modalities
- CAR-T cell therapyCell therapy
- Industry
- Biotech
02
Partnerships
Eureka TherapeuticsLyell ImmunopharmaInitial technology/financial relationships with Juno Therapeutics (now part of Bristol Myers Squibb) and WuXi AppTec
Beyond the preview
Go deeper on JW Capital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JW Capital.